Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Clinical and Genetic Characterization of a Progressive Rbl2-Associated Neurodevelopmental Disorder Publisher Pubmed



Aughey GN1 ; Cali E44 ; Maroofian R44 ; Zaki MS2 ; Pagnamenta AT3 ; Ali Z4 ; Abdulllah U5 ; Rahman F6 ; Menzies L7 ; Shafique A8 ; Suri M9, 10 ; Roze E11 ; Aguennouz M12 ; Ghizlane Z13 Show All Authors
Authors
  1. Aughey GN1
  2. Cali E44
  3. Maroofian R44
  4. Zaki MS2
  5. Pagnamenta AT3
  6. Ali Z4
  7. Abdulllah U5
  8. Rahman F6
  9. Menzies L7
  10. Shafique A8
  11. Suri M9, 10
  12. Roze E11
  13. Aguennouz M12
  14. Ghizlane Z13
  15. Saadi SM14
  16. Fatima A15
  17. Cheema HA16
  18. Anjum MN16
  19. Morel G17
  20. Robin S17
  21. Mcfarland R18, 19
  22. Altunoglu U20
  23. Kraus V21
  24. Shoukier M22
  25. Murphy D23
  26. Flemming K24
  27. Yttervik H25
  28. Rhouda H12
  29. Lesca G26
  30. Chatron N26
  31. Rossi M26, 27
  32. Murtaza BN28
  33. Rehman MU28
  34. Lord J29
  35. Giacopuzzi E30
  36. Hayat A31
  37. Siraj M32
  38. Consortium GE33
  39. Badv RS34
  40. Seo GH35
  41. Beetz C36
  42. Kayserili H20
  43. Krioulie Y12
  44. Chung WK37
  45. Naz S8
  46. Maqbool S6
  47. Chandler KE38
  48. Kershaw CJ38
  49. Wright T38, 39
  50. Banka S38, 39
  51. Gleeson JG40, 41
  52. Taylor JC3
  53. Efthymiou S44
  54. Baig SM15, 42
  55. Severino M43
  56. Jepson JEC1
  57. Houlden H44
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom
  2. 2. Department of Clinical Genetics, Human Genetics and Genome Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt
  3. 3. NIHR Oxford Biomedical Research Centre, Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, United Kingdom
  4. 4. Centre for Biotechnology and Microbiology, University of Swat, Charbagh, Swat, Khyber Pakhtunkhwa, 19120, Pakistan
  5. 5. University Institute of Biochemistry and Biotechnology (UIBB), PMAS-Arid Agriculture University Rawalpindi, Rawalpindi, 46300, Pakistan
  6. 6. Department of Developmental-Behavioral Pediatrics, The Children’s Hospital, University of Child Health Sciences (UCHS-CH), Lahore, 54600, Pakistan
  7. 7. Department of Clinical Genetics, Great Ormond Street Hospital for Children NHS Foundation Trust, London, WC1N 3JH, United Kingdom
  8. 8. School of Biological Sciences, University of the Punjab, Lahore, 54590, Pakistan
  9. 9. UK National Paediatric Ataxia Telangiectasia Clinic, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom
  10. 10. Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom
  11. 11. INSERM, CNRS, Sorbonne University, Paris Brain Institute, Salpetriere Hospital/AP-HP, Paris, 75013, France
  12. 12. Department of Clinical and Experimental Medicine, University of Messina, Messina, 98122, Italy
  13. 13. Unit of Neuropediatrics and Neurometabolism, Pediatric Department 2, Rabat Children’s Hospital, Rabat, BP 6527, Morocco
  14. 14. Human Molecular Genetics Laboratory, NIBGE-PIEAS, Faisalabad, 61010, Pakistan
  15. 15. Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi City, Sindh, Karachi, 74800, Pakistan
  16. 16. Department of Paediatric Gastroenterology, Hepatology and Genetic Diseases, Children’s Hospital, University of Child Health Sciences, Punjab, Lahore, 54000, Pakistan
  17. 17. Service de Genetique, CHU (Centre Hospitalier Universitaire) de La Reunion, Reunion Island, Saint-Denis, 97400, France
  18. 18. Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom
  19. 19. NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE2 4HH, United Kingdom
  20. 20. Medical Genetics Department, School of Medicine (KUSoM), Koc University, Istanbul, 34450, Turkey
  21. 21. Technical University of Munich, Faculty of Medicine, Chair of Social Pediatrics, Heiglhofstr. 65, Munich, 81377, Germany
  22. 22. Prenatal Medicine Munich, Lachnerstrasse 20, Munich, 80639, Germany
  23. 23. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom
  24. 24. Department of Pediatric Rehabilitation, University Hospital Northern Norway, Tromso, 9019, Norway
  25. 25. Department of Medical Genetics, University Hospital of North Norway, Tromso, 9038, Norway
  26. 26. Genetics Department, Hospices Civils de Lyon, Lyon, 69002, France
  27. 27. GENDEV Team, CRNL, INSERM U1028, CNRS UMR 5292, UCBL1, Lyon, 69675, France
  28. 28. Department of Zoology, Abbottabad University of Science and Technology, KP, 22500, Pakistan
  29. 29. Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, S10 2HQ, United Kingdom
  30. 30. Technopole, Milan, 20157, Italy
  31. 31. Department of MLT, Abbottabad University of Science and Technology KP, Abbottabad, 22500, Pakistan
  32. 32. Department of Zoology, Abbottabad University of Science and Technology KP, Abbottabad, 22500, Pakistan
  33. 33. Genomics England, London, E14 5AB, United Kingdom
  34. 34. Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, 14197 33151, Iran
  35. 35. 3billion inc, 416 Teheran-ro, Gangnam-gu, Seoul, South Korea
  36. 36. Department of Genomic Insights, Centogene GmbH, Rostock, 18055, Germany
  37. 37. Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, 02115, MA, United States
  38. 38. Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, M13 9WL, United Kingdom
  39. 39. Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, United Kingdom
  40. 40. Department of Neurosciences, University of California, La Jolla, San Diego, 92093, CA, United States
  41. 41. Rady Children’s Institute for Genomic Medicine, San Diego, 92123, CA, United States
  42. 42. Faculty of Life Sciences, Health Services Academy, Islamabad, 44000, Pakistan
  43. 43. UO Neuroradiologia, IRCCS Istituto Giannina Gaslini, Genoa, 16147, Italy
  44. 44. Department of Neuromuscular diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom

Source: Brain Published:2025


Abstract

Retinoblastoma (RB) proteins are highly conserved transcriptional regulators that play important roles during development by regulating cell-cycle gene expression. RBL2 dysfunction has been linked to a severe neurodevelopmental disorder. However, to date, clinical features have been described in only six individuals carrying five biallelic predicted loss-of-function (pLOF) variants. To define the phenotypic effects of RBL2 mutations in detail, we identified and clinically characterized a cohort of 35 patients from 20 families carrying pLOF variants in RBL2, including 15 new variants that substantially broaden the molecular spectrum. The clinical presentation of affected individuals is characterized by a range of neurological and developmental abnormalities. Global developmental delay and intellectual disability were observed uniformly, ranging from moderate to profound and involving lack of acquisition of key motor and speech milestones in most patients. Disrupted sleep was also evident in some patients. Frequent features included postnatal microcephaly, infantile hypotonia, aggressive behaviour, stereotypic movements, seizures and non-specific dysmorphic features. Neuroimaging features included cerebral atrophy, white matter volume loss, corpus callosum hypoplasia and cerebellar atrophy. In parallel, we used the fruit fly, Drosophila melanogaster, to investigate how disruption of the conserved RBL2 orthologue Rbf impacts nervous system function and development. We found that Drosophila Rbf LOF mutants recapitulate several features of patients harbouring RBL2 variants, including developmental delay, alterations in head and brain morphology, locomotor defects and perturbed sleep. Surprisingly, in addition to its known role in controlling tissue growth during development, we found that continued Rbf expression is also required in fully differentiated post-mitotic neurons for normal locomotion in Drosophila, and that adult-stage neuronal re-expression of Rbf is sufficient to rescue Rbf mutant locomotor defects. Taken together, our study provides a clinical and experimental basis to understand genotype–phenotype correlations in an RBL2-linked neurodevelopmental disorder and suggests that restoring RBL2 expression through gene therapy approaches might ameliorate some symptoms caused by RBL2 pLOF. © The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.